<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00036140</url>
  </required_header>
  <id_info>
    <org_study_id>196-ONC-0100-006</org_study_id>
    <nct_id>NCT00036140</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      The primary goal of the study is to determine the best dose of an investigational drug to
      give to patients with multiple myeloma and to evaluate the investigational drug's
      effectiveness as a treatment for multiple myeloma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Investigational drug</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Other specific inclusion/exclusion criteria may apply. In order to determine eligibility,
        further examination by the investigator is necessary.

        Inclusion Criteria:

          -  Eligible patients must be at least 18 years of age with a diagnosis of multiple
             myeloma including elevated M-blood/urine protein or a tumor that can be evaluated by
             the doctor during the investigational drug's treatment.

          -  The patient's multiple myeloma must have gotten worse during/after previous
             chemotherapy was given.

          -  Any side-effects from prior chemotherapy must have subsided

          -  Blood and urine tests must show adequate bone marrow, liver, and kidney function.

        Exclusion Criteria:

        Any of the following will exclude patients from study participation:

          -  indolent or smoldering myeloma or localized plasmacytoma

          -  hyperviscosity syndrome

          -  irradiation to 25% or more of bone marrow

          -  prior high dose chemotherapy with bone marrow or stem cell support

          -  current participation in other clinical trials

          -  pregnant or breast-feeding women

          -  known HIV-positive or AIDS-related illness

          -  patients planning to have radiation therapy or surgery that would interrupt study
             therapy in the next 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2004</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2002</study_first_submitted>
  <study_first_submitted_qc>May 8, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2002</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Pharmacia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

